An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months.

Trial Profile

An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2013

At a glance

  • Drugs Sumatriptan (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Registrational
  • Sponsors NuPathe
  • Most Recent Events

    • 21 Jun 2012 Results will be presented at the 54th Annual Scientific Meeting of the American Headache Society according to a NuPathe media release.
    • 23 Jun 2011 Additional results will be presented at the 15th Congress of the International Headache Society according to a NuPathe Media release.
    • 02 Jun 2011 Long-term results from this trial will be presented at the 53rd Annual Scientific Meeting of the American Headache Society according to a NuPathe media release; results were also summarised in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top